จำหน่ายเกจวัดแรงดัน Pressure Gauge ทุกยี่ห้อ

ศูนย์รวมเครื่องมือวัดความดัน

Acquisition will add to Dover’s single-use component providing

Dover has entered into a definitive settlement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and control instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will broaden Dover’s biopharma single-use manufacturing offering, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate approximately US$40 million–45 million in revenue through the full year 2022.
When the deal closes, Malema will become part of the PSG business unit inside Dover’s Pumps & Process Solutions segment.
“We see an amazing long-term growth alternative within the bioprocessing trade driven by a robust and rising pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of extra environment friendly single-use production processes supports a robust outlook for our offerings of single-use components to end-customers. We imagine that pairing Malema’s expertise with our present portfolio of single-use pumps for biopharma processing will greatly improve the accuracy and worth proposition of our solutions to our customers.”
“We are methodically building out our biopharma platform through proactive capacity additions, new product development, and opportunistic acquisitions of highly-attractive niche element applied sciences,” stated Richard Tobin, president and CEO of Dover. “ pressure gauge ออก หลัง represents a strategic and highly-complementary flow-control and sensing technology and additional strengthens our sensor portfolio with new proprietary technology. In addition to engaging biopharma applications, we anticipate strong growth within the semiconductor house on the capacity growth and re-shoring tailwinds.”
Share